Skip to content
Endologix is now Rhevera Medical. Learn more about our evolution.
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Peripheral
Pounce System
DETOUR System
DETOUR System Reimbursement
DETOUR Professional Education
For PAD Patients
Find a Doctor
Aortic
AAA
ALTO
AFX2
EVAR for Women
EVAR Portfolio Resources
Clinical Evidence
Procedural Training
IFUs
About Us
About Rhevera
News
The Team
Careers
Internal Applicant Portal
External Applicant Portal
Investigator-Initiated Research
Contact Us
Search
Back to News
November 17, 2016
Positive Two-Year Data from the Nellix® EVAS FORWARD Global Registry Presented at 2016 VEITH Symposium
Prev
Previous
Positive Five-Year Results from the Global Ovation® Pivotal Trial Presented at 2016 VEITH Symposium
Next
Endologix Receives Australian Therapeutic Goods Administration (TGA) Approval for AFX®2 Bifurcated Endograft System
Next
